MedPath

Investigational study on immunomodulatory effect of lenvatinib in clinical specimens - Future oriented approach for lenvatinib on tumor microenvironment and cancer regression (FLORENCE)

Not Applicable
Conditions
Hepatocellular carcinoma
Registration Number
JPRN-UMIN000044924
Lead Sponsor
Hiroshima University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Lenvatinib was administered after second-line therapy Informed consent for analysis was withdrawn

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the immuno-stimulatory effect of lenvatinib and the change of immune system through lenvatinib treatment using tumor samples by identifying immune cell profiling in tumor tissue before and after lenvatinib treatment
Secondary Outcome Measures
NameTimeMethod
Progression-free survival, Overall survival
© Copyright 2025. All Rights Reserved by MedPath